AstraZeneca Expands Bengaluru Hub to Drive AI-Powered Healthcare Innovation

Glimpse:

Investment: INR 166 Crore
Location: Bengaluru, Karnataka
Jobs Created: 400 new roles (total 1,300 at the facility)
Focus Areas:
Advanced clinical research
AI-powered healthcare solutions
Digital health technologies
Centralized data analytics
Strategic Goal: Deliver 20 new medicines by 2030
🇮🇳 India Presence: Over 4,000 employees
Recent Expansion: Global Innovation and Technology Centre (GITC), Chennai

“This step reflects our commitment to tapping into the world-class talent and ecosystem available in Karnataka.”

— Jackie Crockford, VP, Global Business Services, AstraZeneca

In a bold move to supercharge its R&D capabilities and harness the power of AI in healthcare, biopharma giant AstraZeneca has announced a significant expansion of its global hub in Bengaluru, India. With an investment of INR 166 crore, this expansion underscores the company’s long-term vision to reshape the future of medicine through cutting-edge technology and data-driven solutions.

The expanded facility is designed to be a nucleus for advanced clinical research, AI-powered healthcare solutions, digital health technologies, and centralized data analytics—all aimed at improving clinical trial outcomes and accelerating the delivery of life-changing treatments. The site will now house approximately 1,300 employees, adding 400 new jobs and bringing AstraZeneca’s total workforce in India to over 4,000.

“Our Global Hub in Bengaluru is a strategic investment that will play a vital role in advancing AstraZeneca’s bold ambition to deliver 20 new medicines by 2030, by strengthening automated, scalable, data-driven, and patient-centric solutions,” said Jackie Crockford, Vice President, Global Business Services, AstraZeneca. “This step reflects our commitment to tapping into the world-class talent and ecosystem available in Karnataka to power the next generation of scientific innovation.”

Doubling Down on India’s Innovation Ecosystem

This development marks AstraZeneca’s second major India investment in less than a year, following the expansion of its Global Innovation and Technology Centre (GITC) in Chennai. Together, these hubs represent the company’s deepening roots in India’s rapidly evolving biotech and digital health landscape.

“This hub enhances our R&D capabilities by connecting us with India’s exceptional scientific and technological expertise,” added Magnus Nord, Vice President, Global Patient Safety BioPharma, AstraZeneca. “The expansion will accelerate the development of innovative medicines and help us deliver across R&D, ultimately benefiting patients around the world.”

Pioneering the Future of Healthcare

The Bengaluru hub is poised to become a cornerstone of AstraZeneca’s global operations, with a strong focus on AI-enabled R&D, global business services, IT infrastructure, and digital health operations. It aligns with the company’s broader goal of building an ecosystem that combines human intelligence with machine learning to solve complex healthcare challenges more efficiently and effectively.

As the world races toward a more connected, tech-forward healthcare model, AstraZeneca’s latest investment not only cements India’s role as a vital R&D destination but also signals a transformative shift in how medicines are developed and delivered—faster, smarter, and more patient-centric than ever before.

🎧 Listen to the Summary

Get the key points in just a minute!

💡 Visual Summary

Understand the article in under 60 seconds.